Neurophet, an artificial intelligence (AI) corporations for diagnosing and treating brain diseases, said on the 10th that it will participate in the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2026), to be held in Copenhagen, Denmark, from the 17th to the 21st (local time).
Neurophet will showcase its comprehensive brain imaging analysis solution for prescribing Alzheimer's disease treatments, "Neurophet AQUA AD Plus," at its conference exhibition booth.
The software quantitatively analyzes MRI (magnetic resonance imaging) and PET (positron emission tomography) images to support evaluation of a patient's eligibility for a prescription before treatment administration, monitoring of side effects during administration, and analysis of treatment effectiveness after administration. It received U.S. Food and Drug Administration (FDA) 510(k) clearance (premarket notification) last month.
It will also introduce the neurodegeneration imaging analysis software "Neurophet AQUA" and the PET image quantitative analysis software "Neurophet SCALE PET."
The company will also present two research abstracts on Alzheimer's disease brain image analysis at this conference. The main research topics are ▲ Deep Learning–based partitioning of amyloid-related imaging abnormalities (ARIA) and hemorrhagic lesions of cerebral amyloid angiopathy ▲ a comparative study of centiloid analysis using MR fusion and PET alone against ADNI thresholds in amyloid PET.
Neurophet will also seek business collaborations at this conference with global big pharma and contract research organizations (CROs). In particular, it plans to introduce Imaging Core Lab (ICL), a neuroimaging biomarker analysis service used in clinical trials for Alzheimer's and Parkinson's disease treatments.
Bin Jun-gil, co-CEO of Neurophet, said, "Neurophet AQUA AD Plus is drawing growing interest from medical institutions at home and abroad in the field of imaging analysis related to prescribing Alzheimer's disease treatments," adding, "We will focus on expanding strategic partnerships with global pharmaceutical companies through this conference."